Search Results

Dipharma Francis S.r.l. proudly announced that Dipharma Inc., its US facility located in Kalamazoo, MI, has been inspected by the U.S. Food and Drug Administration and has received the Establishment Inspection Report, satisfactorily closing the inspection process.

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.

Dipharma Francis S.r.l. announced the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan, in the North of Italy.

Dipharma Francis S.r.l. announced the completion of the second phase of expansion of its American site, Dipharma Inc., located in Kalamazoo, MI.

Dipharma Francis S.r.l., a leading Contract Development and Manufacturing Organization and a global manufacturer of Active Pharmaceutical Ingredients, announced another new production site of the Group, thefacility located in Caronno Pertusella, near Milan, has received the Good Manufacturing Practice certification - CBPF - from the Regulatory Authority of Brazil, ANVISA.